Comparative Pharmacology
Head-to-head clinical analysis: MEROPENEM versus MERREM IV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MEROPENEM versus MERREM IV.
MEROPENEM vs MERREM IV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Meropenem inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP 2 and PBP 3, leading to cell death.
Meropenem is a carbapenem antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell death.
1-2 g IV every 8 hours, infused over 15-30 minutes; typical dose 1 g q8h for complicated infections. Extended infusion over 3 hours may be used for resistant organisms.
1 g intravenously every 8 hours over 15-30 minutes for complicated intra-abdominal infections; 500 mg intravenously every 8 hours for complicated skin and skin structure infections.
None Documented
None Documented
Clinical Note
moderateMeropenem + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Meropenem."
Clinical Note
moderateMeropenem + Valproic acid
"The serum concentration of Valproic acid can be decreased when it is combined with Meropenem."
Clinical Note
moderateMeropenem + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Meropenem."
1.0-1.5 hours in adults with normal renal function; prolonged to 4-6 hours in moderate renal impairment (CrCl 10-50 mL/min) and up to 7-10 hours in severe renal impairment (CrCl <10 mL/min).
Terminal elimination half-life approximately 1 hour in adults with normal renal function; prolonged to 4–6 hours in moderate renal impairment and up to 10 hours in severe impairment; clinical context: dosing interval adjustment required for CrCl <50 mL/min.
Renal: 70% unchanged via glomerular filtration and tubular secretion. Biliary: <2% excreted in bile. Fecal: ~2%.
Primarily renal (approximately 70% as unchanged drug) via glomerular filtration and tubular secretion; biliary/fecal excretion accounts for ~20% as microbiologically inactive metabolite; minimal nonrenal clearance.
Category A/B
Category C
Carbapenem Antibiotic
Carbapenem Antibiotic